louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05917197: Impact of Social Media on the Development of Anorexia Nervosa
Official title: Assessing the Impact of Social Media on the Development of Anorexia Nervosa in Undergraduate Students-A Cross Sectional Study From a Developing Country
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: The Focus of Study Were the Medical Students Whose Eating Behaviors Were Studied
Lead sponsor: Jinnah Sindh Medical University
Sponsor class: OTHER
First posted: 2023-06-23
Enrollment: 214
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Medical students of Karachi

Brief summary: The study involves the recruitment of medical students from all government medical colleges of Karachi,Pakistan. The sample size was 214. The study is a cross sectional study that requires the participants to fill out an online questionnaire after giving an informed consent online.

Detailed description: The study involves the recruitment of medical students from all government medical colleges of Karachi, Pakistan. The sample size was 214. The study is a cross sectional study that requires the participants to fill out an online questionnaire after giving an informed consent online.The questionnaire contained 15 items related to their social media use and its impact on their body image and eating behaviours.

Eligibility criteria: Inclusion Criteria:

* Medical students of Karachi
* All should be aged 18 to 25 years
* Both genders included

Exclusion Criteria:

* Non consenting participants
* Those who donot have access to social media

Primary outcomes:
measure: Social media use
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Sindh
Study officials:
affiliation: Jinnah Sindh Medical University
name: Areeba Ismail
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01328197: Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
Official title: A Phase I Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Abdominal Aortic Aneurysms
Keywords: Treovance
aneurysm
AAA
Lead sponsor: Bolton Medical
Sponsor class: INDUSTRY
First posted: 2011-04-04
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: AAA device
Primary purpose: TREATMENT

Brief summary: The primary goal of the study is to assess the safety and performance of the Treovance device in subjects with infrarenal aortic aneurysms, specifically to evaluate if the diseased pathology can be treated with an acceptable adverse event rate and that the device performs as expected. The results of this study will permit the establishment of endpoints and clinical design for a subsequent U.S. trial.


Eligibility criteria: Inclusion Criteria:

* Subjects with diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement
* Subjects with an infrarenal AAA that is \>/= 4.5 cm in diameter for males, or \>/= 4.0 cm in diameter for females, or has increased in diameter by 0.5 cm in the last 6 months
* Subjects who consent to participate
* Subjects who agree to comply with the follow-up schedule

Exclusion Criteria:

* Subjects with dissections, ruptured aneurysms, or symptomatic aneurysms
* Subjects with prior AAA repair
* Subjects with medical conditions that would complicate the endovascular procedure or confound results (e.g., Marfan's syndrome, morbid obesity, severe coronary artery disease)
* Subjects who are pregnant or lactating
* Subjects participating in other investigational studies
* Subjects with less than 2 years life expectancy

Primary outcomes:
measure: major morbidity and mortality
timeFrame: 1, 6, 12 months
Secondary outcomes:
measure: Device performance
timeFrame: implant, 1, 6, and 12 months
Other outcomes:
Locations:
city: Worcester
country: United States
facility: University of Massachusetts
state: Massachusetts
city: Grand Rapids
country: United States
facility: Spectrum Health System
state: Michigan
city: Charlotte
country: United States
facility: Carolinas Sanger Heart and Vascular
state: North Carolina
city: Greenville
country: United States
facility: East Carolina University
state: North Carolina
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
city: Norfolk
country: United States
facility: Sentara Heart Hospital
state: Virginia
Study officials:
References:
Clinical trial NCT03405597: HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg
Official title: HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in some cases serum HBsAg level declines to unmeasurable level. Some of patients develop anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion.

There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV infection and lost their HBsAg without seroconversion to anti-HBsAb.


Eligibility criteria: Inclusion Criteria:

Chronic Hepatitis B infection group

* 18-80 year-old
* Compensated liver disease
* Chronic HBV infection with or without NUCs treatment
* History of HBsAg positive \> 6 months
* HBsAg negative with qualitative Elecsys (Roche) twice at least 6 months apart
* HBsAb negative
* HBV DNA \< 20 IU/mL

Healthy group

* Healthy person without history of HBV vaccination (HBsAg, anti-HBc and HBsAb negative)

Exclusion Criteria:

* History of previous HBV vaccination
* Anti-HCV and/or anti-HIV positive
* Decompensated cirrhosis
* History of previous malignancies
* History or currently receive immunotherapy, cytotoxic or immunosuppressive agents
* Patient with immunodeficiency disease
* Creatinine \> 1.5 mg/dL
* Pregnancy or lactating woman
* Unable to consent

Primary outcomes:
measure: HBsAb level at 4 weeks after complete vaccine injection
timeFrame: an average of 7 months
Secondary outcomes:
measure: HBsAb level at 6 months after complete vaccine injection
timeFrame: an average of 1 year
measure: Adverse event from HBV vaccine
timeFrame: an average of 1 year
measure: Factors associated with HBV vaccine response
timeFrame: an average of 1 year
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Faculty of Medicine Siriraj Hospital
state: Bangkok
Study officials:
affiliation: Department of Medicine, Faculty of medicine Siriraj Hospital, Mahidol University
name: Tawesak Tanwandee
role: PRINCIPAL_INVESTIGATOR
References:
citation: Taheri H, Hasanjani Roushan MR, Soleimani Amiri MJ, Pouralijan M, Bijani A. Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg. Hepat Mon. 2011 Feb;11(2):119-22.
Clinical trial NCT05202197: Smart Cupboard-based System for Memory Assessment in Alzheimer's Patients
Official title: Smart Cupboard-based System for Memory Assessment in Alzheimer's Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer Disease
Cognitive Decline
Lead sponsor: Universidad de Zaragoza
Sponsor class: OTHER
First posted: 2022-01-21
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community dwelling Alzheimer's patients who attend the Alzheimer's and dementia center in Teruel on a regular basis.

Brief summary: The main objective of the research is to create a tool that can make a good diagnosis of cognitive abilities in Alzheimer's patients. As a secondary objective, the investigators intend to examine both the percentage of correct answers and the response times and see their relationship with age, gender, sex, months since the onset of the disease and years of training.


Eligibility criteria: Inclusion Criteria:

1. Being over 18 years.
2. Provide signed informed consent.
3. Have the ability to understand the study.

Exclusion Criteria:

Having any physical or medical problem that prevents or advises them not to stand upright, in a bipedal position.

Primary outcomes:
measure: Accuracy response.
timeFrame: 60 minutes
measure: Reaction time
timeFrame: 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Teruel
country: Spain
facility: University of Zaragoza
Study officials:
References:
Clinical trial NCT06827197: Role of Interleukin-1β and Prostaglandin E2 in Prediction and Outcome of Apnea in Neonates
Official title: Role of Interleukin-1β and Prostaglandin E2 in Prediction and Outcome of Apnea in Neonates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Premature Newborns
Premature Newborns With Gestational Age 28 to 33 Weeks
Keywords: Apnea of prematurity
Interleukin-1β
Prostaglandin E2
Outcome
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2025-02-14
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study included 100 preterm neonates who were recruited from the Neonatal Intensive Care Unit, Pediatric Department of Benha University Hospital, during the period from May 2023 till October 2023. They were eligible for the study and their parents agreed to participate in the study.

Brief summary: Our thesis proposed that IL-1β may affect brainstem respiratory control via prostaglandin-dependant mechanism so we investigated the mediator roles of IL-1β and PGE2 levels in predicting apnea in pretertm newborn and their relation to clinical outcomes.


Eligibility criteria: Inclusion Criteria:

* Preterm infants born at less than 37 weeks of gestation.
* Neonates aged from birth up to 28 days.
* Neonates diagnosed with apnea of prematurity or exhibiting apneic episodes

Exclusion Criteria:

* Full-term neonates.
* Neonates with major congenital malformations or genetic syndromes.
* Neonates with severe neurological impairments (e.g., intraventricular hemorrhage grade III or IV).
* Neonates with confirmed or suspected sepsis or active infections.
* Neonates receiving steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications known to alter interleukin-1β or prostaglandin E2 levels.
* Neonates with congenital heart diseases.
* Neonates with a history of significant birth asphyxia requiring extensive resuscitation.
* Neonates whose parents or guardians refuse to provide informed consent.

Primary outcomes:
measure: Duration of NICU stay
timeFrame: 1 month
measure: Mortality rate
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Benha University
state: Al-Qalyubia
city: Banhā
country: Egypt
facility: Amany El-Rebigi
Study officials:
References:
Clinical trial NCT01508897: Comparison of Two Liraglutide Formulations in Healthy Volunteers
Official title: A Randomized, Single-blind, Single-centre, Two-period, Cross-over Trial Investigating the Bioequivalence Between Completed Phase 2 and Planned Phase 3 Formulations of Liraglutide in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes
Healthy
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2012-01-12
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of two formulations of liraglutide.


Eligibility criteria: Inclusion Criteria:

* Good general health as judged by the investigator, based on medical history, physical examination including 12-lead ECG (electrocardiogram), vital signs and blood and urinary laboratory assessments
* Body Mass Index (BMI) of 18-27 kg/m\^2 incl.

Exclusion Criteria:

* History of any clinically significant renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric disease or other major disorders that may interfere with the objectives of the study, as judged by the investigator
* Impaired renal function
* Uncontrolled treated/untreated hypertension
* Any clinically significant abnormal ECG
* Active hepatitis B and/or active hepatitis C
* Positive HIV (human immunodeficiency virus) antibodies
* History of alcoholism or drug abuse during the last 12 months
* Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products
* Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the Investigator
* Excessive consumption of a diet deviating from a normal diet as judged by the Investigator

Primary outcomes:
measure: Area under the Curve (AUC) (0-t)
measure: Cmax, maximum concentration
Secondary outcomes:
measure: AUC (0-infinity)
measure: tmax, time to maximum concentration
measure: t½, terminal half-life
measure: Terminal elimination rate constant
measure: Adverse events
Other outcomes:
Locations:
city: Neu-Ulm
country: Germany
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT03302377: Fit for Two: Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes (FFT)
Official title: Fit for Two: Feasibility and Acceptability of Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Activity
Type 2 Diabetes Mellitus
Keywords: Feasibility
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2017-10-05
Enrollment: 19
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: As this is a feasibility study, all participants will receive the intervention
Primary purpose: PREVENTION

Brief summary: This study will investigate the feasibility of an intervention to increase physical activity in pregnant women with diabetes by incorporating a brief in-person counseling session and Fitbit activity trackers into routine clinical care

Detailed description: This is a small, one-armed pilot study testing a physical activity intervention for pregnant patients with diabetes. The intervention will use both counseling and technology (a FitBit physical activity tracker and smartphone app) to create an individualized, interactive program for each patient. The primary aims of the study are to assess the feasibility of recruiting patients and implementing the program in the clinical setting, and the acceptability of the program for patients and clinicians. Participants will receive a counseling session based on the principles of motivational interviewing to help them set physical activity and step goals, then the interventionist will help them personalize the Fitbit app to their goals. Participants are instructed to continue adaptive goal setting and email their goals and activity weekly to their physicians. In addition to assessing feasibility and acceptability, we will also evaluate change in activity to explore potential efficacy.

Eligibility criteria: Inclusion Criteria:

* diagnosed with type 2 diabetes or gestational diabetes
* currently pregnant
* in week 5-25 of gestation
* under active (\<100 minutes/week of physical activity)
* access to a smartphone

Exclusion Criteria:

* any medical condition that would make unsupervised activity unsafe or unfeasible, as determined by their physician
* moving from the area within 3 months

Primary outcomes:
measure: Retention
timeFrame: 12 weeks
measure: Acceptability
timeFrame: 12 weeks
measure: Feasibility of recruitment
timeFrame: baseline
Secondary outcomes:
measure: Physical activity change
timeFrame: 12 weeks
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: University of California, San Diego
state: California
Study officials:
References:
citation: Larsen B, Micucci S, Hartman SJ, Ramos G. Feasibility and Acceptability of a Counseling- and mHealth-Based Physical Activity Intervention for Pregnant Women With Diabetes: The Fit for Two Pilot Study. JMIR Mhealth Uhealth. 2020 Oct 21;8(10):e18915. doi: 10.2196/18915.
Clinical trial NCT05157477: Targeting the Sensory Disturbance in Autism Spectrum Disorder
Official title: Targeting the Sensory Disturbance in Autism Spectrum Disorder: The Effectiveness of Cognitive-behavior Therapy-based Virtual Reality Exposure Program
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Autistic Disorders Spectrum
Keywords: autism spectrum; sensory disturbance; intervention; virtual reality; cognitive behavior therapy
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-12-15
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to establish a cognitive-behavior therapy (CBT) based virtual exposure (VR) exposure program to train ASD adults coping with everyday sensory scenarios. Through the practice and training, the ASD participants may learn the strategy to deal with the common sensory scenarios and master the anxiety around the exposure. The anticipatory anxiety and the maladaptive behaviors may be decreased along with the process of desensitization, while the functional impairment related to sensory sensitivity can partly be recovered.


Eligibility criteria: Inclusion Criteria:

* young adult aged between 18 and 45 years who had a diagnosis of ASD from a licensed mental health or medical professional based on DSM-5;
* has sensory and social problems as reported by the participant and the caregiver;
* is motivated to participate in the treatment;
* is fluent in Chinese;
* has a full-scale IQ \> 70 on WAIS-IV;
* scored ≧ 26 on the caregiver-reported Autism Spectrum Quotient (AQ), indicating clinical impairment associated with ASD.

Exclusion Criteria:

* A history of major mental illness (e.g., bipolar affective disorder, schizophrenia, or psychosis) or neurological diseases;
* visual impairment and/or hearing impairment that would preclude participation in the CBT-based VR exposure program

Primary outcomes:
measure: The change of heart rate
timeFrame: Two months, first time in the first week and second time in the last week.
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT01734577: Effect of Dry Needling Multifidus on Thickness of Transversus Abdominis in Healthy Individuals
Official title: The Effect of Trigger Point Dry Needling to the Multifidus Muscle on Resting and Contracted Thickness of Transversus Abdominis in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Back Pain
Keywords: Back pain
Lead sponsor: University of Nevada, Las Vegas
Sponsor class: OTHER
First posted: 2012-11-27
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Intramuscular therapy (also known as dry needling) has been shown to give dramatic relief of musculoskeletal pain. The mechanisms of action remain unknown, and this study will examine for a neurophysiological effect.

Detailed description: Consenting adults will be taught how to contract their abdominal muscles, and to contract transversus abdominis in particular. They will then have real time ultrasound measurements of the resting and contracted thickness of their left transversus abdominis muscle. After this, they will receive actual or sham needling to their left multifidus muscle by another researchers blinded to the real time ultrasound measurements. After needling or sham intervention is complete, the original researchers will return to re-measure transversus abdominis. They will be blind to intervention allocation.

Eligibility criteria: Inclusion Criteria:

* Age, absence of back pain or symptoms for greater than 6 months and ability to perform DCC. Subjects must also report they are comfortable with being 'needled'.

Exclusion Criteria:

* Presence of back pain or symptoms within the last 6 months, history of: abdominal or spinal surgery, significant scoliosis, rheumatoid arthritis, osteoporosis, osteopenia, active ankylosing spondylitis. If a subject reports a fear of needles.

Primary outcomes:
measure: Thickness of transversus abdominis at rest and during contraction
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: University of Nevada Las Vegas - Department of Physical Therapy
state: Nevada
Study officials:
affiliation: University of Nevada Las Vegas Physical Therapy
name: Daniella Morton, BSc
role: STUDY_DIRECTOR
affiliation: University of Nevada Las Vegas Physical Therapy
name: Sarah Buckingham, BSc
role: STUDY_DIRECTOR
affiliation: Univesity of Nevada Las Vegas Physical Therapy
name: Crystal Montoya, BSc
role: STUDY_DIRECTOR
References:
citation: Puentedura EJ, Buckingham SJ, Morton D, Montoya C, Fernandez de Las Penas C. Immediate Changes in Resting and Contracted Thickness of Transversus Abdominis After Dry Needling of Lumbar Multifidus in Healthy Participants: A Randomized Controlled Crossover Trial. J Manipulative Physiol Ther. 2017 Oct;40(8):615-623. doi: 10.1016/j.jmpt.2017.06.013.